The vaccine is expected to be commercially ready for the 2025-2026 COVID-19 season. The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...

While CVS hospitalizations have declined, the illness continues to present among young women, Black individuals, and leads to high costs among Hispanic patients.

Adding perioperative systemic therapy to CRS-HIPEC can improve some outcomes in patients with resectable colorectal peritoneal metastases, data suggest.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Providers favor CPAP and patients prefer tirzepatide for treatment for comorbid obesity and obstructive sleep apnea.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Federal health officials pulled back a key recommendation that pregnant women get the COVID-19 vaccine, causing sharp criticism from experts.

Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.